Trastuzumab emtansine

Drug Profile

Trastuzumab emtansine

Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Kadcyla; PRO-132365; R3502; RG 3502; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugate

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Genentech; ImmunoGen
  • Developer Chugai Pharmaceutical; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University of Miami
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 12 Apr 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT02658084)
  • 23 Mar 2017 Roche plans a phase III trial for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/unresectable) in China (NCT03084939)
  • 18 Jan 2017 Roche terminates a phase III trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease, Monotherapy) in South Korea, Malaysia, Thailand and Taiwan (IV) (NCT02144012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top